Platinum-oxazoline complexes as anti-cancer agents: Syntheses, characterisation and initial biological studies

MedChemComm

Volumn 2, Issue 4, 2011, Pages 274-277

  Yadav, Paras N ^a,g   Beveridge, Ramsay E ^a   Blay, Jonathan ^b   Boyd, Alaina R ^a   Chojnacka, Maja W ^c   Decken, Andreas ^d   Deshpande, Ankur A ^a   Gardiner, Michael G ^e   Hambley, Trevor W ^f   Hughes, Michael J ^a   Jolly, Leslie ^e   Lavangie, Jacquelyn A ^a   MacInnis, Timothy D ^a   McFarland, Sherri A ^a   New, Elizabeth J ^f   Gossage, Robert A ^a,c  

^a ACADIA UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c RYERSON UNIVERSITY   (Canada)

^d UNIVERSITY OF NEW BRUNSWICK   (Canada)

^e UNIVERSITY OF TASMANIA   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g TRIBHUVAN UNIVERSITY   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 2 OXAZOLINE; 4,4 DIMETHYL 2 [O ANILINYL] 2 OXAZOLINE; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; OXAZOLINE DERIVATIVE; PLATINUM OXAZOLINE COMPLEX; PYRIDINE 2 CARBOXYANIL[O (4,4 DIMETHYL 2 OXAZOLINYL) IDE]; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DNA ADDUCT; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; X RAY DIFFRACTION;

EID: 79953840928     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c0md00211a     Document Type: Article

References (31)

1. (a) N. J. Wheate, S. Walker, G. E. Craig and R. Oun, Dalton Trans., 2010, 39, 8113;
2. (b) B. Lippert (Ed.), Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH: Oxford, 1999.
3. (a) T. W. Hambley, Dalton Trans., 2007, 4929;
4. (b) R. A. Alderden, M. D. Hall and T. W. Hambley, J. Chem. Educ., 2006, 83, 728.
5. M. Gielen and E. R. T. Tiekink (ed.), Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: the Use of Metals in Medicine, Wiley-VCH: Toronto, 2005.
6. (a) A.M. Montaña and C. Batalla, Curr. Med. Chem., 2009, 16, 2235;
7. (b) E. Wong and C. M. Giandomenico, Chem. Rev., 1999, 99, 2451;
8. (c) B. W. Harper, A. M. Krause-Heuer, M. P. Grant, M. Manohar, K. B. Garbutcheon-Singh and J. R. Aldrich-Wright, Chem. Eur. J., 2010, 16, 7064.
9. M. D. Hall, H. R. Mellor, R. Callaghan and T. W. Hambley, J. Med. Chem., 2007, 50, 3403.
10. T. Eicher and S. Hauptmann, The Chemistry of Heterocycles, 2nd Ed., Wiley-VCH: Weinheim, 2003, Ch. 5.23-5.25.
11. (a) For example: R. A. Gossage, P. N. Yadav, T. D. MacInnis, J. W. Quail and A. Decken, Can. J. Chem., 2009, 87, 368;
12. (b) F. J. Baerlocher, R. Bucur, A. Decken, C. R. Eisnor, R. A. Gossage, S. M. Jackson, L. Jolly, S. L. Wheaton and R. S. Wylie, Aust. J. Chem., 2010, 63, 47.
13. F. P. Intini, A. Boccarelli, V. C. Francia, C. Pacifico, M. F. Sivo, G. Natile, D. Giordano, P. De Rinaldis and M. Coluccia, J. Biol. Inorg. Chem., 2004, 9, 768.
14. A. Decken, R. A. Gossage and P. N. Yadav, Can. J. Chem., 2005, 83, 1185.
15. +).
16. -3. Selected bond lengths (Å) and angles (°): Pt-Cl1 2.305(1), Pt-Cl2 2.299(2), Pt-N1 1.995(4), Pt-N2 2.042(7), N1-C2 1.282(9); Cl1-Pt-Cl2 91.79(6), Cl1-Pt-N1 179.0(2), Cl1-Pt-N2 90.3(2), N1-Pt-N2 88.9(2) Cl1-N2-C7 121.1(6).
17. 2), 6.65 (m, 1H, Ar H), 6.82 (m, 1H, Ar H), 7.28 (m, 1H, Ar H), 7.63 (m, 1H, Ar H). Anal. Calc. (Found): C 28.96 (28.44); H 3.09 (2.97); N 6.14 (6.13)%. Crystals suitable for X-ray diffraction work were obtained by recrystallisation of 2 from aq. 95% EtOH at RT.
18. -3. Selected bond lengths (Å) and angles (°): Pt-Cl1 2.294(3), Pt-Cl2 2.324(3), Pt-N1 2.043(7), Pt-N2 2.06(1), N1-C5 1.28(1); Cl1-Pt- Cl2 88.3(1), Cl1-Pt-N1 174.1(2), Cl1-Pt-N2 90.6(3), N1-Pt-N2 84.3(3) Pt1-N2-C7 110.0(7).
19. 2). Anal. Calc. (Found): C 25.87 (25.65); H 3.91 (3.51); N 6.03 (6.01)%.
20. Full details on the X-ray structural characterisation of complex 3 will be published separately: Gossage, R. A.; Jenkins, H. A. unpublished results.
21. L. J. Farrugia, J. Appl. Crystallogr., 1997, 30, 565.
22. (a) For example: P. N. Yadav, R. A. Gossage and A. Decken, Anal. Sci., 2008, 24, x301;
23. (b) A. Albinati, H. Moriyama, H. Rüegger, P. S. Pregosin and A. Togni, Inorg. Chem., 1985, 24, 4430;
24. (c) R. A. Michelin, R. Bertani, M. Mozzon, G. Bombieri, F. Benetollo and R. J. Angelici, Organometallics, 1991, 10, 1751;
25. (d) U. Belluco, R. Bertani, F. Meneghetti, R. A. Michelin, M. Mozzon, G. Bandoli and A. Dolmella, Inorg. Chim. Acta, 2000, 300, 912;
26. (e) Y. Chen, Z. Guo, S. Parsons and P. J. Sadler, Chem.-Eur. J., 1998, 4, 672.
27. 50 values were determined as the drug concentration that reduced the absorbance to 50% of that in untreated control wells.
28. J. Carmichael, W. G. DeGraff, A. F. Gazdar, J. D. Minna and J. B. Mitchell, Cancer Res., 1987, 47, 936.
29. M. V. Keck and S. J. Lippard, J. Am. Chem. Soc., 1992, 114, 3386.
30. S. F. Bellon, J. H. Coleman and S. J. Lippard, Biochemistry, 1991, 30, 8026.
31. R. A. Gossage in Experiments in Green and Sustainable Chemistry (ed.: H. W. Roesky and D. K. Kennepohl), Wiley-VCH, Weinheim, 2009, Ch. 4.